Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 178-183

  Macías, Juan ^a   Orihuela, Francisco ^b   Rivero, Antonio ^c   Viciana, Pompeyo ^d   Márquez, Manuel ^e   Portilla, Joaquín ^f   Ríos, María J ^g   Muñoz, Leopoldo ^h   Pasquau, Juan ⁱ   Castaño, Manuel A ^b   Abdel Kader, Laila ^a   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^h HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

HBV; HCV; Hepatotoxicity; Liver fibrosis

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PROTECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; RISK FACTOR; SIDE EFFECT;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PYRIDINES; PYRONES; RITONAVIR; TRANSAMINASES;

EID: 57749113641     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn429     Document Type: Article

References (24)

1. Cahn P, Villacian J, Lazzarin A et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43: 1347-56.
2. Gathe J, Cooper DA, Farthing C et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43: 1337-46.
3. Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir -ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
4. Mauss S, Stern J, Elgadi M et al. RESIST 24-week efficacy and safety of tipranavir boosted with ritonavir (TPV/r) in hepatitis B (HBV) or hepatitis C (HCV) co-infected patient. In: Abstracts of the Tenth European AIDS Conference, Dublin, Ireland, 2005. Abstract PE13.3/4.
5. Aptivus. Full prescribing information, including boxed warnings. Updated in October 2007. www.aptivus.com.
6. Pineda JA, Santos J, Rivero A et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008; 61: 925-32.
7. Vergara S, Macías J, Rivero A et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C coinfection. Clin Infect Dis 2007; 45: 969-74.
8. Macías J, Girón-González JA, González-Serrano M et al. Prediction of liver fibrosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut 2006; 55: 409-14.
9. Scheuer PJ. Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991; 13: 372-4.
10. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
11. Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007; 45: S57-65.
12. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992-1002.
13. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: Data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39: 1507-13.
14. Sulkowski MS, Mehta SH, Chaisson RE et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-84.
15. Benhamou Y, Mats V, Walczak D. Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and co-infected with HCV. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 88. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Sherman KE, Shire NJ, Cernohous P et al. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: Lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005; 41: 1186-95.
17. Palacios R, Vergara S, Rivero A et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials 2006; 7: 319-23.
18. Sulkowski M, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
19. Pol S, Benhamou Y, Rockstroh J et al. Hepatic profile of tipranavir in treatment experienced HIV-1 infected individuals. In: Abstracts of the Eleventh European AIDS Conference Madrid, Spain, 2007 Abstract P4.5/03.
20. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
21. Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196 670-6.
22. Mira JA, Macías J, Girón-González JA et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006; 58: 140-6.
23. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services, 29 January 2008. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
24. Sulkowski MS, Mehta SH, Torbenson MS et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-16.